Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia
e17371 - ?
MetadataShow full item record
Chlorproguanil-dapsone (Lapdap), developed as a low-cost antimalarial, was withdrawn in 2008 after concerns about safety in G6PD deficient patients. This trial was conducted in 2004 to evaluate the safety and effectiveness of CD and comparison with artemether-lumefantrine (AL) under conditions of routine use in G6PD normal and G6PD deficient patients with uncomplicated malaria in The Gambia. We also examined the effects of a common genetic variant that affects chlorproguanil metabolism on risk of treatment failure.
AuthorsDunyo, S; Sirugo, G; Sesay, S; Bisseye, C; Njie, F; Adiamoh, M; Nwakanma, D; Diatta, M; Janha, R; Sisay Joof, F; Temple, B; Snell, P; Conway, D; Walton, R; Cheung, YB; Milligan, P
- College Publications